Filgrastim-sndz

BIOLOGICAL8 trials

Sponsors

M.D. Anderson Cancer Center

Conditions

Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositiveAcute Biphenotypic LeukemiaAcute LeukemiaAcute Lymphoblastic LeukemiaAcute Lymphoblastic Leukemia in RemissionAcute Myeloid LeukemiaAcute Myeloid Leukemia Arising From Previous Myelodysplastic SyndromeAcute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11

Phase 1

Donor Natural Killer Cells in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

CompletedNCT01787474

M.D. Anderson Cancer CenterRecurrent Adult Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia

Start: 2014-05-19End: 2021-06-17Updated: 2021-06-21

Pomalidomide, Dexamethasone, and Filgrastim-sndz in Treating Patients With Relapsed or Refractory Multiple Myeloma

TerminatedNCT01946152

M.D. Anderson Cancer CenterMultiple Myeloma-Light Chain Only, Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma

Start: 2014-03-05End: 2020-03-18Updated: 2021-07-30

Melphalan Hydrochloride in Treating Participants With Newly-Diagnosed Multiple Myeloma Undergoing Donor Stem Cell Transplantation

CompletedNCT03417284

M.D. Anderson Cancer CenterPlasma Cell Myeloma

Start: 2019-10-09End: 2024-07-18Updated: 2025-05-01

Bendamustine With or Without Cyclophosphamide in Preventing GVHD in Patients Undergoing Stem Cell Transplant

RecruitingNCT04022239

M.D. Anderson Cancer CenterHematopoietic and Lymphoid System Neoplasm

Start: 2020-03-13End: 2027-07-31Target: 25Updated: 2026-01-12

Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

TerminatedNCT05032183

M.D. Anderson Cancer CenterRecurrent Adult Lymphoblastic Lymphoma, Recurrent B Acute Lymphoblastic Leukemia, Recurrent T Acute Lymphoblastic Leukemia +3

Start: 2022-02-17End: 2024-07-31Updated: 2025-08-11

Phase 2

Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

RecruitingNCT00801489

M.D. Anderson Cancer CenterAcute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11, Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11, Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1 +7

Start: 2007-04-04End: 2028-10-11Target: 270Updated: 2026-03-30

Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or Lymphoma

CompletedNCT03096782

M.D. Anderson Cancer CenterAccelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Biphenotypic Leukemia, Acute Leukemia +19

Start: 2017-10-13End: 2022-09-20Updated: 2023-10-11

Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Leukemia or Lymphoma Undergoing Stem Cell Transplantation

TerminatedNCT03856216

M.D. Anderson Cancer CenterAcute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, Lymphocytic Neoplasm +1

Start: 2019-10-28End: 2025-10-13Updated: 2025-10-16

Related Papers

Therapy related core binding factor Acute Myeloid Leukemia (CBF-AML) responds favorably to fludarabine, cytarabine, GCSF (FLAG) based therapy: Exploratory Analysis from a Phase 2 trial

Blood2025-11-03

Gemtuzumab Ozogamicin Added to Fludarabine, Cytarabine and G-CSF (FLAG-GO) Leads to Superior Molecular Response and Survival Outcomes Than Idarubicin (FLAG-IDA): 200 Patients Long-Term Follow up

Blood2024-11-052 citations

A Phase I, Single-Arm, Open Label, Dose Escalation, Multicenter Study of Off-the-Shelf Natural Killer (NK) Cells (SAR445419) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)

Blood2023-11-021 citations

Initial results of two phase I trials delivering mbIL-21 ex vivo expanded haploidentical NK cells after fludarabine/cytarabine for patients with relapsed/refractory myeloid leukemias.

Journal of Clinical Oncology2018-05-206 citations

A Phase I/II Study of Pomalidomide and Dexamethasone with Growth Factor Support in Patients with Relapsed/Refractory Multiple Myeloma

Blood2017-12-07

Minimal residual disease eradication with epigenetic therapy in core binding factor acute myeloid leukemia

American Journal of Hematology2017-05-1148 citations

Prognostic Impact of Kinase Mutations and Minimal Residual Disease in Core-Binding Factor Leukemia

Blood2015-12-03